|
|
|
prIME Oncology invites you to view prIME Downloadable Slides in multiple myeloma and myeloproliferative neoplasms that focus on new hematology data from the 2011 Annual Hematology Meeting in San Diego.
|
|
|
Release Date
December 21, 2011
|
Expiration Date
December 21, 2012 |
|
Target Audience
This educational activity is specifically designed for hematologists, oncologists, and other healthcare providers involved or interested in the treatment of patients with hematologic malignancies. |
Overview
These slide decks cover recently released data from the 2011 Annual Hematology Meeting in San Diego, focusing on various aspects of the management of patients with hematologic malignancies. |
Educational Objectives
Upon completion of this educational activity, participants should be able to:
- Discuss the most recent clinical trial data regarding treatment of patients with multiple myeloma and myeloproliferative neoplasms
- Describe emerging therapies and novel treatment strategies for patients with hematologic malignancies
- Examine the efficacy and safety of various treatment modalities for hematologic malignancies, with a focus
on those that reduce the severity of patient symptoms and improve quality of life
|
Sponsorship
This activity is sponsored by prIME Oncology. |
Continuing Medical Education
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Each slide set may provide the following credits:
2011614-1 (MM Relapsed/Refractory): 1.25 credits
2011614-2 (MM Front-Line): 2.0 credits
2011614-3 (MPN): 1.75 credits
|
Support Statement
This activity is supported by unrestricted educational grants from Incyte and Onyx Pharmaceuticals. |
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you.
Links to the post tests are available on the slide pages.
|
Disclosure of Conflicts of Interest
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The employees of prIME Oncology have disclosed:
- Chelsey Goins, PhD (clinical) – no relevant financial relationships to disclose
- Trudy Stoddert, ELS (editorial) – no relevant financial relationships to disclose
- Heather Tomlinson, MA (editorial) – no relevant financial relationships to disclose
- Susan H Yarbrough, CCMEP (compliance) – no relevant financial relationships to disclose
|
Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings. |
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
|
|
 |
|
|
|
|
|
